Emmes, a global, full-service CRO, has appointed Wendy Buckland as chief operating officer, leading global operations.
 

Prior to joining the company, Buckland headed PPD’s neuroscience therapeutic unit where she was responsible for strategy, client satisfaction, operational delivery, profitability and talent development, as well as oversight for all clinical development programs in neuroscience and ophthalmology.
 
Emmes Chief Executive Officer Dr. Christine Dingivan said, “Wendy has an outstanding reputation with an impressive track record for building high-performing teams and leading client accounts. Her depth in clinical operations in many different parts of the world will add immediate value to our leadership and operations team.”
 
Buckland held four different vice president roles at PPD over a period of nearly seven years: clinical development, Latin America; governance, risk and compliance; global quality and compliance; and strategic partnerships. Her prior clinical operations posts included senior positions overseeing Europe, the Middle East, Africa and Australia, followed by responsibility for emerging regions in Latin America and Asia.
 
Dr. Dingivan added, “The range of positions Wendy has held will have a direct, positive impact on Emmes as we expand globally and add more biopharma research work. Her involvement in neurology, ophthalmology, rare disease, and cell and gene therapy is important too, as we continue to expand our presence in these important therapeutic areas.”
 
Buckland began her career at PPD in 1998 as clinical operations manager in Johannesburg, South Africa. Previously, she spent eight years at Novartis in South Africa. Buckland holds a pharmacy bachelor’s degree from the University of Witwatersrand, South Africa, and a diploma in business management from the Damelin Management School.